Astellas Pharma Inc. is making significant strides in the biotech market, with numerous innovations, partnerships and product developments. They have entered an exclusive option and license agreement with
AviadoBio for Gene Therapy AVB-101, targeting Frontotemporal Dementia and other indications. They also recently unveiled a new
Life Sciences Center in Cambridge, Massachusetts to accelerate the discovery of breakthrough therapies. Furthermore, FDA approved Astellas'
gastric cancer therapy, revealing its commitment towards transforming cancer treatment. In a landmark deal, Astellas inked a US$2.2bn gene therapy agreement with
AviadoBio Ltd. It also received FDA listing for
DIGITIVA™ for the management of heart failure, reflecting Astellas' innovative drive. However, on the downside, the company is recalling medication for preventing organ transplant rejection due to potentially empty capsules. A company employee has also been indicted by China's prosecutors.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Fri, 27 Dec 2024 10:02:37 GMT -
Rating 5
- Innovation 8
- Information 9
- Rumor -3
